Skip to content

Investigation of Brain Network Dynamics in Depression

Investigation of Cortico-limbic Networks and Their Dynamics in Major Depressive Disorder

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01931995
Enrollment
45
Registered
2013-08-30
Start date
2013-02-28
Completion date
2018-07-31
Last updated
2021-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder, Recurrent

Brief summary

This research study is being done to gain a better understanding about brain networks that may be involved in depression. The investigators plan to examine how these networks change after the brain is stimulated with Transcranial Magnetic Stimulation (TMS). TMS is a way of stimulating the brain in order to mildly activate or mildly suppress different brain areas, and is used to treat some forms of depression. It is hoped that this study will facilitate learning more about the structure and function of different brain areas and the ways that they are interconnected to form networks, both in depressed people and in people without depression. In this research study, the effects of TMS will be measured by obtaining pictures of the brain with Magnetic Resonance Imaging (MRI) and with Positron Emission Tomography (PET). More specifically, this will be accomplished with a combined MRI and PET scanner, which is capable of simultaneously obtaining both MRI and PET images of the brain. This scanning paradigm will allow the assessment of local metabolic changes resulting from TMS (with PET images) and brain network changes resulting from TMS (with fMRI). Changes resulting from TMS between 20 subjects with depression and 20 healthy volunteers will be calculated and will form the main outcome measure.

Detailed description

Repetitive transcranial magnetic stimulation (rTMS), when delivered to the dorsolateral prefrontal cortex (DLPFC) is a clinically effective treatment for major depressive disorder (MDD). Network models of MDD are increasingly gaining acceptance, and functional connectivity MRI (fcMRI) has revealed topographically specific aberrations in functional network architecture in MDD. And yet, despite hints that the therapeutic effects of rTMS are actuated through distributed impacts upon cortical and subcortical limbic centers, the network effects of rTMS remain mysterious. This study seeks to investigate the way rTMS to DLPFC modulates network functional connectivity between the site of stimulation and a critical limbic region, the subgenual cingulate (sgACC), and between the sgACC and other limbic regions. In this study, high frequency rTMS will be used to stimulate the left DLPFC (recapitulating the therapeutic methodology), specifically, regions of the DLPFC that are functionally correlated and anti-correlated with the sgACC. This will be accomplished in a group of patients with MDD, and in a group of carefully matched controls. These subjects will be scanned before and after rTMS is delivered, as a way of gauging its effects. The feasibility of this design was recently demonstrated by our group (Eldaief et al. PNAS 2011). Changes induced by the stimulation will be charted with a novel combined MRI-PET (Positron Emission Tomography) scanner at the MGH Martinos Center, which is capable of simultaneously recording fcMRI BOLD (Blood oxygenation level-dependent) and 18Flurodeoxyglucose (FDG) PET data. This will permit cortico-limbic networks to be characterized dynamically through (1) examination of the differential effects of stimulating two networks in the DLPFC, and (2) by tracking the dynamic interplay between rTMS induced changes in local glucose metabolism at DLPFC and sgACC on the one hand, and changes in distributed connectivity between these regions on the other. In an exploratory aim, MDD patients will return three months later (after they have undergone a non-specific treatment intervention with their psychiatric provider) for the identical rTMS/fcMRI/FDG-PET procedures. This aim will establish, as proof of principle, that treatment of MDD is associated with changes in cortico-limbic functional network architecture, and in cortico-limbic dynamics. Eventually, it is hoped that this work will lead to the emergence of aberrant cortical dynamics as a biomarker for MDD. In addition, this work might pollinate future studies which use aberrant cortical dynamics as a novel therapeutic target upon which neuromodulatory interventions might intervene.

Interventions

DEVICETMS positively correlated DLPFC

TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.

PROCEDURETMS to negatively correlated DLPFC

TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Ages 18-50 * Patients with Major Depressive Disorder, as confirmed by a referring provider, DSM-IVR criteria, and/or a Structured Clinical Interview (SCID) * Score of ≥18 on the 24 item version of the Hamilton Depression Rating Scale (HDRS) * Meeting criteria to safely receive fMRI scanning, PET scanning and rTMS.

Exclusion criteria

* Any subject who is pregnant or lactating * Patients with bipolar disorder, schizoaffective disorder, suicidal ideation, or any history of psychosis. Concurrent anxiety disorders will be allowed. * Any serious concurrent medical or neurological illness * Any contraindication to receiving TMS, fMRI or PET scans including, but not limited to having: a pacemaker, metallic implants, implanted pumps, surgical aneurysm clips, history of severe head trauma, history of seizures or a first degree relative with epilepsy, been involved in a nuclear medicine study in the past 12 months, diabetes

Design outcomes

Primary

MeasureTime frameDescription
Relative Changes in Corticolimbic Functional Connectivity as a Result of TMSAssessed immediately following each interventionThe primary outcome measure is the relative change in functional connectivity in prefrontal corticolimbic brain networks resulting from TMS stimulation of two nodes in the dorsolateral prefrontal cortex: one which is positively correlated to the subgenual cingulate and one which is negatively correlated to this area. Functional connectivity is a measure of correlation strength which biologically reflects correlations between low-frequency oscillations in the fMRI blood oxygenation level dependent signal. As a correlation, this ranges from -1 to 1. This is then Fisher transformed from an r value to a z value (range -2 to -2).

Secondary

MeasureTime frameDescription
Changes in Local Glucose Metabolism at Corticolimbic Network NodesAssessed immediately following each intervention.This outcome measure will employ FDG PET scanning to assess changes in local glucose metabolism resulting from TMS to two dorsolateral prefrontal stimulation targets. More specially, changes in glucose metabolism will be assessed at the stimulation targets, in the subgenual cingulate and in the amygdala. This is measured in whole brain normalized standardized uptake values (wbnSUV).

Countries

United States

Participant flow

Recruitment details

45 subjects were recruited between February 2013 and June 2016. All subjects were recruited in Boston, Massachusetts.

Pre-assignment details

45 subjects were enrolled and 37 subjects completed all three sessions. No randomization was done.

Participants by arm

ArmCount
TMS to Positively Correlated DLPFC
High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex TMS positively correlated DLPFC: TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
19
TMS to Negatively Correlated DLPFC
High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex TMS to negatively correlated DLPFC: TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
18
Total37

Withdrawals & dropouts

PeriodReasonFG000FG001
First Intervention (1 Day)Lost to Follow-up11
First Intervention (1 Day)Physician Decision11
First Intervention (1 Day)Withdrawal by Subject22

Baseline characteristics

CharacteristicTMS to Negatively Correlated DLPFCTotalTMS to Positively Correlated DLPFC
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
18 Participants37 Participants19 Participants
Age, Continuous22.7 years
STANDARD_DEVIATION 4
23.9 years
STANDARD_DEVIATION 4
24.8 years
STANDARD_DEVIATION 4
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants2 Participants1 Participants
Race (NIH/OMB)
Black or African American
1 Participants2 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
16 Participants33 Participants17 Participants
Region of Enrollment
United States
37 participants37 participants37 participants
Sex: Female, Male
Female
13 Participants26 Participants13 Participants
Sex: Female, Male
Male
5 Participants11 Participants6 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 370 / 37
other
Total, other adverse events
0 / 370 / 37
serious
Total, serious adverse events
0 / 370 / 37

Outcome results

Primary

Relative Changes in Corticolimbic Functional Connectivity as a Result of TMS

The primary outcome measure is the relative change in functional connectivity in prefrontal corticolimbic brain networks resulting from TMS stimulation of two nodes in the dorsolateral prefrontal cortex: one which is positively correlated to the subgenual cingulate and one which is negatively correlated to this area. Functional connectivity is a measure of correlation strength which biologically reflects correlations between low-frequency oscillations in the fMRI blood oxygenation level dependent signal. As a correlation, this ranges from -1 to 1. This is then Fisher transformed from an r value to a z value (range -2 to -2).

Time frame: Assessed immediately following each intervention

ArmMeasureValue (MEAN)Dispersion
TMS to Positively Correlated DLPFCRelative Changes in Corticolimbic Functional Connectivity as a Result of TMS-0.11 Fisher transformed z valuesStandard Deviation 0.14
TMS to Negatively Correlated DLPFCRelative Changes in Corticolimbic Functional Connectivity as a Result of TMS-0.19 Fisher transformed z valuesStandard Deviation 0.15
Secondary

Changes in Local Glucose Metabolism at Corticolimbic Network Nodes

This outcome measure will employ FDG PET scanning to assess changes in local glucose metabolism resulting from TMS to two dorsolateral prefrontal stimulation targets. More specially, changes in glucose metabolism will be assessed at the stimulation targets, in the subgenual cingulate and in the amygdala. This is measured in whole brain normalized standardized uptake values (wbnSUV).

Time frame: Assessed immediately following each intervention.

ArmMeasureValue (MEAN)Dispersion
TMS to Positively Correlated DLPFCChanges in Local Glucose Metabolism at Corticolimbic Network Nodes-0.06 whole brain normalized suv valuesStandard Error 0.02
TMS to Negatively Correlated DLPFCChanges in Local Glucose Metabolism at Corticolimbic Network Nodes0.054 whole brain normalized suv valuesStandard Error 0.02

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026